• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.维持治疗对新诊断多发性骨髓瘤患者后续治疗的影响：使用“无进展生存期2”作为临床试验终点
Haematologica. 2015 Aug;100(8):e328-30. doi: 10.3324/haematol.2014.120790. Epub 2015 Apr 3.
2
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.来那度胺扩展疗程的卡非佐米-来那度胺-地塞米松治疗冒烟型或新诊断多发性骨髓瘤患者。
JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.
3
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.来那度胺联合化疗与自体移植，随后来那度胺联合泼尼松与来那度胺维持治疗多发性骨髓瘤患者：一项随机、多中心、3 期试验。
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
4
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.自体干细胞移植联合来那度胺维持治疗强化可改善新诊断完全缓解的多发性骨髓瘤患者的生存结局。
Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540. doi: 10.1016/j.clml.2018.05.019. Epub 2018 May 28.
5
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.来那度胺持续治疗新诊断的多发性骨髓瘤。
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
6
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.美法仑、泼尼松和来那度胺治疗后采用来那度胺维持治疗的≥65岁新诊断多发性骨髓瘤患者中影响健康相关生活质量的因素：一项随机试验的结果
Leuk Lymphoma. 2014 Jul;55(7):1489-97. doi: 10.3109/10428194.2013.847933. Epub 2013 Dec 17.
7
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.多发性骨髓瘤患者的维持治疗与生存：系统评价和网络荟萃分析。
JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.
8
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
9
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.硼替佐米-美法仑-泼尼松治疗初诊多发性骨髓瘤后继续来那度胺治疗。
Ann Hematol. 2020 May;99(5):1063-1072. doi: 10.1007/s00277-020-03988-6. Epub 2020 Apr 4.
10
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.

引用本文的文献

1
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.序贯 T 细胞重定向疗法可使复发/难治性骨髓瘤患者获得深度和持久缓解。
Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923.
2
Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.日本在新诊断多发性骨髓瘤老年患者管理方面的最新进展。
Jpn J Clin Oncol. 2022 Sep 18;52(9):966-974. doi: 10.1093/jjco/hyac111.
3
Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis.来那度胺维持治疗慢性淋巴细胞白血病的疗效：一项荟萃分析和试验序贯分析。
Curr Oncol. 2022 Jun 14;29(6):4245-4259. doi: 10.3390/curroncol29060339.
4
How I approach smoldering multiple myeloma.我是如何处理冒烟型多发性骨髓瘤的。
Blood. 2022 Aug 25;140(8):828-838. doi: 10.1182/blood.2021011670.
5
Moving Toward Continuous Therapy in Multiple Myeloma.迈向多发性骨髓瘤的持续治疗
Clin Hematol Int. 2019 Nov 12;1(4):189-200. doi: 10.2991/chi.d.191101.001. eCollection 2019 Dec.
6
Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.组织内环境稳定修复：纠正癌组织异常内环境稳定——超越诱导凋亡
Front Oncol. 2019 Dec 20;9:1408. doi: 10.3389/fonc.2019.01408. eCollection 2019.
7
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.免疫检查点抑制剂作为实体瘤的桥接或延续维持治疗：原理和现状。
Target Oncol. 2019 Oct;14(5):505-525. doi: 10.1007/s11523-019-00665-1.
8
Conference report on the 28th annual meeting of the European Musculo-Skeletal Oncology Society, 29 April-1 May 2015, Athens.2015年4月29日至5月1日于雅典举行的欧洲肌肉骨骼肿瘤学会第28届年会会议报告
Ecancermedicalscience. 2015 Jul 8;9:550. doi: 10.3332/ecancer.2015.550. eCollection 2015.

本文引用的文献

1
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤患者的持续治疗与固定疗程治疗的比较。
J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17.
2
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.来那度胺联合地塞米松治疗不适合移植的骨髓瘤患者。
N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.
3
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.硼替佐米-马法兰-泼尼松-沙利度胺序贯治疗随后硼替佐米-沙利度胺维持治疗与硼替佐米-马法兰-泼尼松方案比较用于初治多发性骨髓瘤：更新随访结果和改善生存。
J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.
4
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.泊马度胺联合低剂量地塞米松与高剂量地塞米松单独用于治疗复发和难治性多发性骨髓瘤（MM-003）患者：一项随机、开放标签、3 期试验。
Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3.
5
Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.多发性骨髓瘤患者自体干细胞移植后使用免疫调节药物的维持治疗：一项随机对照试验的荟萃分析。
PLoS One. 2013 Aug 19;8(8):e72635. doi: 10.1371/journal.pone.0072635. eCollection 2013.
6
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.一项单药卡非佐米（PX-171-003-A1）治疗复发/难治性多发性骨髓瘤患者的 II 期研究。
Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.
7
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.来那度胺维持治疗多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.
8
Lenalidomide after stem-cell transplantation for multiple myeloma.来那度胺用于多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.
9
Continuous lenalidomide treatment for newly diagnosed multiple myeloma.来那度胺持续治疗新诊断的多发性骨髓瘤。
N Engl J Med. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704.
10
The genetic architecture of multiple myeloma.多发性骨髓瘤的遗传结构。
Nat Rev Cancer. 2012 Apr 12;12(5):335-48. doi: 10.1038/nrc3257.

Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.

作者信息

Dimopoulos Meletios A, Petrucci Maria T, Foà Robin, Catalano John, Kropff Martin, Terpos Evangelos, Zhang Jingshan, Grote Lara, Jacques Christian, Palumbo Antonio

机构信息

University of Athens School of Medicine, Greece

Sapienza University of Rome, Italy.

出版信息

Haematologica. 2015 Aug;100(8):e328-30. doi: 10.3324/haematol.2014.120790. Epub 2015 Apr 3.

DOI:10.3324/haematol.2014.120790
PMID:25840600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5004436/
Abstract
摘要